GlassScriptPhysician profile
Navin Ramlal
NPI 1306228903
$1,402.54
in general payments reported to CMS, 2019-2025
13 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $169 · 2021: $63.10 · 2022: $311 · 2023: $328 · 2024: $397 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $671.58 | 2020-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $181.45 | 2020-2024 | Zerbaxa, Dificid, Recarbrio |
| Innovation Technologies INC | $165.66 | 2024 | Irrisept |
| Abiomed | $93.36 | 2025 | |
| Ucb, INC. | $79.26 | 2023 | Briviact |
| E.R. Squibb & Sons, L.L.C. | $68.08 | 2020-2022 | |
| Pfizer INC. | $35.28 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $30.90 | 2021-2022 | |
| Portola Pharmaceuticals, LLC | $21.27 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.72 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.59 | 2025 | Terlivaz |
| La Jolla Pharmaceutical Company | $11.37 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Ramlal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.